NHGRI logo
Democratizing Education for  Sickle Cell Disease Gene Therapy Project logo

Resources for healthcare providers

CMS sickle cell disease action plan

FDA-approved gene therapies for sickle cell disease

Casgevy and Lyfgenia: Two Gene Therapies for Sickle Cell Disease  The Medical Letter


Exagamglogene autotemcel


Lovotibeglogene autotemcel 

Clinical trials

Learn About Studies  ClinicalTrials.gov

a family with a young girl high-fiving her doctor

Sickle cell disease gene therapy education project

The Democratizing Education for Sickle Cell Disease Gene Therapy project developed patient-focused educational materials for the sickle cell community.

Understanding the blood cell

Learn about the different types of hemoglobin.

Doctor and patient

Understanding gene therapy approaches

A variety of approaches target the blood stem cells to relieve or reduce your symptoms of sickle cell disease.

Doctor and patient consultation

Navigating sickle cell disease gene therapy

Gene therapy for sickle cell disease is available to you through FDA-approved therapies and through clinical trials.

Your mental health and gene therapy

Your mental and physical health are deeply connected. Mental health is important for your overall health and quality of life.

A couple in discussion

Sickle cell disease gene therapy FAQ

Discuss these questions with your doctor or health care provider.

family with a young girl reviewing forms with a healthcare worker

Patient resources for sickle cell disease gene therapy

Sickle cell disease resources for patients

The Democratizing Education Project welcomes your feedback about the sickle cell disease gene therapy resources. Please email your comments or questions to DemocratizingEd@mail.nih.gov.

These educational materials are for informational purposes only. They are meant to promote your general understanding of gene therapy for sickle cell disease. We encourage you to use these educational materials to talk with your healthcare provider or a clinical trial team.

Last updated: September 27, 2024